BR112022010223A2 - Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp) - Google Patents
Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp)Info
- Publication number
- BR112022010223A2 BR112022010223A2 BR112022010223A BR112022010223A BR112022010223A2 BR 112022010223 A2 BR112022010223 A2 BR 112022010223A2 BR 112022010223 A BR112022010223 A BR 112022010223A BR 112022010223 A BR112022010223 A BR 112022010223A BR 112022010223 A2 BR112022010223 A2 BR 112022010223A2
- Authority
- BR
- Brazil
- Prior art keywords
- tslp
- polypeptides
- variable domains
- immunoglobulin variable
- single immunoglobulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945391P | 2019-12-09 | 2019-12-09 | |
| EP20305064 | 2020-01-27 | ||
| PCT/EP2020/085304 WO2021116182A1 (en) | 2019-12-09 | 2020-12-09 | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010223A2 true BR112022010223A2 (pt) | 2022-09-06 |
Family
ID=73793214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010223A BR112022010223A2 (pt) | 2019-12-09 | 2020-12-09 | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp) |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20210188965A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4072674A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7641968B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102984686B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114980974A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020400938A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022010223A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163910A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022008813A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293548A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007035A (cg-RX-API-DMAC7.html) |
| MY (1) | MY208649A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI861302B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021116182A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| CN114980974A (zh) | 2019-12-09 | 2022-08-30 | 艾伯霖克斯公司 | 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 |
| WO2022063984A1 (en) * | 2020-09-25 | 2022-03-31 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| CA3217029A1 (en) * | 2021-05-30 | 2022-12-08 | Biolojic Design Ltd. | Engineered dual binding antibodies and uses thereof |
| KR20250025381A (ko) | 2022-06-17 | 2025-02-21 | 아포지 바이오로직스, 인크. | 인터류킨 13에 결합하는 항체 및 사용 방법 |
| WO2024017915A1 (en) * | 2022-07-18 | 2024-01-25 | Ablynx N.V. | Cx3cr1-binding compounds, uses thereof and related methods |
| CN118005784A (zh) | 2022-11-08 | 2024-05-10 | 上海洛启生物医药技术有限公司 | 抗il-13长效纳米抗体序列及其应用 |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| IL322519A (en) | 2023-02-17 | 2025-10-01 | Ablynx Nv | Polypeptides that bind to the neonatal fc receptor |
| AU2024247861A1 (en) | 2023-03-24 | 2025-11-06 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| EP4435005A1 (en) | 2023-03-24 | 2024-09-25 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| EP4731663A2 (en) * | 2023-06-22 | 2026-04-29 | Paragon Therapeutics, Inc. | Antibodies that bind interleukin 13 and tslp or tslpr and methods of use |
| AR133647A1 (es) | 2023-08-25 | 2025-10-22 | Proteologix Us Inc | Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos |
| AR134101A1 (es) * | 2023-10-12 | 2025-12-03 | Innovent Biologics Suzhou Co Ltd | Anticuerpos anti-tslp y usos de los mismos |
| WO2025209486A1 (en) * | 2024-04-02 | 2025-10-09 | Keymed Biosciences (Chengdu) Co., Ltd. | Antibodies targeting il-13 and tslp and uses thereof |
| WO2026041740A1 (en) | 2024-08-21 | 2026-02-26 | Sanofi | Treatment of high-risk asthma by blocking il-13 and tslp |
| WO2026055143A2 (en) * | 2024-09-03 | 2026-03-12 | Attovia Therapeutics, Inc. | Il13-binding polypeptides and uses thereof |
| WO2026067440A1 (zh) * | 2024-09-29 | 2026-04-02 | 四川科伦博泰生物医药股份有限公司 | Tslp/il-13双特异性抗体及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US20100113339A1 (en) * | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
| AR064333A1 (es) * | 2006-12-14 | 2009-04-01 | Schering Corp | Anticuerpo anti-tslp de diseno |
| CA2744588A1 (en) * | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Ligands that bind il-13 |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| LT3466972T (lt) | 2011-06-23 | 2026-06-25 | Ablynx Nv | Serumo albuminą surišantys baltymai |
| LT3248986T (lt) | 2014-05-16 | 2022-03-25 | Ablynx Nv | Imunoglobulino kintami domenai |
| CN107428828A (zh) * | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
| HUE057241T2 (hu) | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| US10544222B2 (en) * | 2015-11-18 | 2020-01-28 | Merck Sharp & Dohme Corp. | PD1/CTLA4 binders |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| CA3006398A1 (en) * | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| US11248057B2 (en) * | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| US11840569B2 (en) | 2016-11-16 | 2023-12-12 | Ablynx N.V. | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| WO2018104444A1 (en) | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3571224B1 (en) | 2017-01-17 | 2024-08-07 | Ablynx NV | Improved serum albumin binders |
| EP4442709A3 (en) | 2017-01-17 | 2024-12-25 | Ablynx NV | Improved serum albumin binders |
| KR20260100427A (ko) * | 2018-03-28 | 2026-06-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
| CN112687354B (zh) * | 2019-01-29 | 2022-07-12 | 杭州纽安津生物科技有限公司 | 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法 |
| CN114980974A (zh) | 2019-12-09 | 2022-08-30 | 艾伯霖克斯公司 | 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
-
2020
- 2020-12-09 CN CN202080085549.9A patent/CN114980974A/zh active Pending
- 2020-12-09 IL IL293548A patent/IL293548A/en unknown
- 2020-12-09 JP JP2022534664A patent/JP7641968B2/ja active Active
- 2020-12-09 TW TW109143498A patent/TWI861302B/zh active
- 2020-12-09 AU AU2020400938A patent/AU2020400938A1/en active Pending
- 2020-12-09 BR BR112022010223A patent/BR112022010223A2/pt unknown
- 2020-12-09 MX MX2022007035A patent/MX2022007035A/es unknown
- 2020-12-09 TW TW113137609A patent/TW202530257A/zh unknown
- 2020-12-09 WO PCT/EP2020/085304 patent/WO2021116182A1/en not_active Ceased
- 2020-12-09 US US17/115,906 patent/US20210188965A1/en not_active Abandoned
- 2020-12-09 KR KR1020227023385A patent/KR102984686B1/ko active Active
- 2020-12-09 EP EP20823785.9A patent/EP4072674A1/en active Pending
- 2020-12-09 MY MYPI2022002971A patent/MY208649A/en unknown
- 2020-12-09 CA CA3163910A patent/CA3163910A1/en active Pending
-
2021
- 2021-11-19 US US17/530,850 patent/US12492248B2/en active Active
- 2021-11-19 US US17/530,727 patent/US12384840B2/en active Active
- 2021-11-19 US US17/530,800 patent/US11840566B2/en active Active
-
2022
- 2022-06-24 CO CONC2022/0008813A patent/CO2022008813A2/es unknown
-
2025
- 2025-02-20 JP JP2025025563A patent/JP2025081540A/ja active Pending
- 2025-11-12 US US19/386,343 patent/US20260152549A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12492248B2 (en) | 2025-12-09 |
| MY208649A (en) | 2025-05-22 |
| US20220177564A1 (en) | 2022-06-09 |
| TW202136302A (zh) | 2021-10-01 |
| US20220177566A1 (en) | 2022-06-09 |
| KR102984686B1 (ko) | 2026-07-01 |
| EP4072674A1 (en) | 2022-10-19 |
| US20220177565A1 (en) | 2022-06-09 |
| CA3163910A1 (en) | 2021-06-17 |
| MX2022007035A (es) | 2022-06-23 |
| JP2023504914A (ja) | 2023-02-07 |
| US20260152549A1 (en) | 2026-06-04 |
| US20210188965A1 (en) | 2021-06-24 |
| JP7641968B2 (ja) | 2025-03-07 |
| CN114980974A (zh) | 2022-08-30 |
| KR20220123237A (ko) | 2022-09-06 |
| WO2021116182A1 (en) | 2021-06-17 |
| TW202530257A (zh) | 2025-08-01 |
| AU2020400938A1 (en) | 2022-07-28 |
| CO2022008813A2 (es) | 2022-07-19 |
| US11840566B2 (en) | 2023-12-12 |
| IL293548A (en) | 2022-08-01 |
| US12384840B2 (en) | 2025-08-12 |
| TWI861302B (zh) | 2024-11-11 |
| JP2025081540A (ja) | 2025-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007035A (es) | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp. | |
| MX2022006881A (es) | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. | |
| AR120698A1 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp | |
| Nicolaidou et al. | Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation | |
| MX2024010771A (es) | Anticuerpos multiespecificos y usos de estos. | |
| ZA202107047B (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
| WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| BR112022001902A2 (pt) | Proteína biespecífica de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica e método para a produção da proteína biespecífica de ligação ao antígeno | |
| MX2021003608A (es) | Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente. | |
| CO2023002989A2 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y ox40l | |
| BR112022004986A2 (pt) | Anticorpos anti-tnfr2 e métodos de uso | |
| MX394165B (es) | Anticuerpos anti-receptor ccr7 humanizados. | |
| BR112021018608A2 (pt) | Anticorpos para claudina-6 e conjugados de fármaco | |
| BR112022009799A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23 | |
| BR112012028326A2 (pt) | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos | |
| PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| EA202092088A1 (ru) | Антитела анти-phf-тау и их применение | |
| BR112022004603A2 (pt) | Anticorpo anti-cd371 ou um fragmento de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico, vetor de expressão, célula hospedeira, métodos e kit | |
| ZA202305329B (en) | Multi-specific antibodies and antibody combinations | |
| BR112022010824A2 (pt) | Anticorpo bifuncional contra pd-l1 e tgf¿ | |
| PH12017500332A1 (en) | Antigen binding proteins that bind cxcr3 | |
| Gao et al. | Upregulated KAT7 in synovial fibroblasts promotes Th17 cell differentiation and infiltration in rheumatoid arthritis | |
| MX2023013392A (es) | Anticuerpos para tratar alfa-sinucleinopatias. | |
| BR112023008365A2 (pt) | Anticorpos antiantígeno de sars-cov-2 e composições e métodos relacionados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024023752-0 PROTOCOLO 870240097416 EM 13/11/2024 18:06. |